In adults with systemic lupus erythematosus (SLE), antinucleosome antibodies have already been described as markers of disease activity and lupus nephritis.\(^1\)\(^-\)\(^4\) In addition, anti-C1q and antinucleosome antibodies have an amplifying effect on the etiopathogenesis of lupus nephritis in adults.\(^5\) In this issue of the Brazilian Journal of Rheumatology, Jesus et al.\(^6\) have clearly shown the association of those antibodies with lupus nephritis, indicating that they could be a potential biomarker of renal lesion in juvenile SLE. In a previous study, that same group of researchers had already demonstrated the association of antinucleosome antibodies with disease activity, but not with lupus nephritis.\(^7\) One of the major concerns of rheumatologists is to identify a test that can be used in the follow-up of patients with SLE, both adult and juvenile, especially for establishing disease activity and its correct diagnosis. Thus, the study by Jesus et al.\(^6\) has shown that anti-C1q and antinucleosome antibodies have high specificity and elevated positive predictive value (over 97%) to diagnose lupus, being considered reliable instruments for clinical practice. Finally, those authors have also suggested that anti-C1q and antinucleosome antibodies should be measured in the investigation of lupus, especially in patients with juvenile SLE, who test negative for anti-dsDNA antibodies.

Paulo Louzada-Junior
Max Victor Carioca Fretas
Editors-in-chief, Brazilian Journal of Rheumatology
REFERENCES
REFERÊNCIAS


